Dietary supplement trade organizations will participate Wednesday in a briefing to congressional staff to promote legislative proposals that would direct the Food and Drug Administration to regulate hemp-derived CBD, the U.S. Hemp Roundtable announced.
At noon E.T. at 2247 Rayburn House Office Building, U.S. Hemp Roundtable General Counsel Jonathan Miller will moderate a panel of representatives from the American Herbal Products Association (AHPA), Council for Responsible Nutrition (CRN), Consumer Healthcare Products Association (CHPA) and United Natural Products Alliance (UNPA), according to a U.S. Hemp Roundtable media advisory.
The discussion will focus on three bills: H.R.1628, CBD Product Safety and Standardization Act; H.R.1629, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act; and S.2451, Hemp Access and Consumer Safety Act.
“Tomorrow will be a critical day for the hemp industry and our prospects for ensuring FDA regulation of CBD,” Miller said in an email to Natural Products Insider. “We’ll have more than 50 sit-down meetings with members of Congress and their staffs and expect over 80 key congressional staff to attend our briefing with the dietary supplement organizations. We have a lot of educating to do, but we are confident that when our voices are heard, progress on hemp and CBD will ensue.”
FDA’s inaction on hemp regulation has severely impacted…